Director/PDMR Shareholding

RNS Number : 0714U

e-Therapeutics plc

17 June 2009

 



Press Release

17 June 2009

e-Therapeutics plc

('e-Therapeutics' or 'the Company')

Director's shareholding

e-Therapeutics plc (AIM: ETX), the systems biology drug discovery company, announces that on 18 March 2009, the Self Invested Pension Plan of John Cordiner acquired, in aggregate, 5,000 ordinary shares of 0.1p each in the Company ('Ordinary Shares') at an average price of 34p per share. Following this acquisition, John Cordiner and his Self Invested Pension Plan have in aggregate an interest in 367,060 Ordinary Shares, which represents 0.6 % of the current issued share capital of the Company.

- Ends -

For further information:

e-Therapeutics plc www.etherapeutics.co.uk  Malcolm Young [e-mail] [phone] Nominated Advisor: WH Ireland Katy Mitchell [e-mail]  [phone]

Broker: Cornhill Asset Management Tom Whitehead [e-mail]  [phone] Andrew Houchin [e-mail]  [phone]

Media enquiries:

Abchurch www.abchurch-group.com Heather Salmond [e-mail] Tel: [phone] Stephanie Cuthbert [e-mail] Tel: [phone] Simone Alves  [e-mail]  Tel: [phone]

Notes to Editors

e-Therapeutics plc is a systems biology drug discovery company. It has developed proprietary computational systems to swiftly and accurately analyse and predict how medicines interact with cells in the body. This optimises the probability of identifying drug candidates with desirable efficacy and low toxicity. The Company applies its novel, systematic approach to three areas of activity: 

	discovery of new drugs;
	discovering novel uses for existing drugs; and
	analysis of the interactions between different drugs.

Amongst e-Therapeutics' pipeline of compounds in development are novel antibiotics that have been shown to kill the 'superbug' MRSA, and a novel cancer chemotherapy that has been shown to kill malignant cells at safe doses in a very short time. Other candidate therapies in development are targeted at atherosclerosis, asthma and depression. The Company is currently in negotiation with a number of pharmaceutical companies, and is progressing the preclinical and clinical development of these products. 

For further information on e-Therapeutics visit www.etherapeutics.co.uk

 

END

 

 

RDSILFIERFIDLIA